vs
BIOMERICA INC（BMRA）与Anbio Biotechnology（NNNN）财务数据对比。点击上方公司名可切换其他公司
Biomerica Inc.是一家全球性医疗技术企业，研发、生产及销售诊断检测试剂盒与相关医疗产品，产品线覆盖胃肠疾病、传染病、食物不耐受检测及即时检测解决方案，服务全球多地的临床实验室、医疗机构及零售医疗客户。
Anbio Biotechnology是一家专注于体外诊断领域的生物技术企业，主要从事快速检测试剂及相关配套产品的研发、生产与销售，产品覆盖传染病检测、心血管标志物检测、食品安全筛查等多个领域，客户遍及全球多个国家和地区。
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收
BMRA
NNNN
| Q4 25 | $1.2M | — | ||
| Q3 25 | $1.4M | — | ||
| Q2 25 | $749.0K | — | ||
| Q1 25 | $1.1M | — | ||
| Q4 24 | $1.6M | — | ||
| Q3 24 | $1.8M | — | ||
| Q2 24 | $1.1M | — | ||
| Q1 24 | $1.0M | — |
净利润BMRANNNN
| Q4 25 | $-1.3M | — | ||
| Q3 25 | $2.0K | — | ||
| Q2 25 | $-1.5M | — | ||
| Q1 25 | $-1.2M | — | ||
| Q4 24 | $-950.0K | — | ||
| Q3 24 | $-1.3M | — | ||
| Q2 24 | $-1.4M | — | ||
| Q1 24 | $-1.9M | — |
毛利率BMRANNNN
| Q4 25 | 4.2% | — | ||
| Q3 25 | 30.7% | — | ||
| Q2 25 | -33.0% | — | ||
| Q1 25 | 1.7% | — | ||
| Q4 24 | 26.7% | — | ||
| Q3 24 | 16.0% | — | ||
| Q2 24 | 2.1% | — | ||
| Q1 24 | -14.7% | — |
营业利润率BMRANNNN
| Q4 25 | -113.5% | — | ||
| Q3 25 | -81.0% | — | ||
| Q2 25 | -209.1% | — | ||
| Q1 25 | -108.1% | — | ||
| Q4 24 | -60.7% | — | ||
| Q3 24 | -75.7% | — | ||
| Q2 24 | -136.6% | — | ||
| Q1 24 | -196.7% | — |
净利率BMRANNNN
| Q4 25 | -109.1% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | -206.1% | — | ||
| Q1 25 | -103.9% | — | ||
| Q4 24 | -58.1% | — | ||
| Q3 24 | -72.8% | — | ||
| Q2 24 | -127.1% | — | ||
| Q1 24 | -188.6% | — |
每股收益（稀释后）BMRANNNN
| Q4 25 | $-0.45 | — | ||
| Q3 25 | $0.00 | — | ||
| Q2 25 | $-0.99 | — | ||
| Q1 25 | $-0.48 | — | ||
| Q4 24 | $-0.06 | — | ||
| Q3 24 | $-0.63 | — | ||
| Q2 24 | $-2.57 | — | ||
| Q1 24 | $-0.11 | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
